Cargando…

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

Objective. To evaluate health-related quality of life (HRQOL) and corticosteroid use in patients with moderate to severely active SLE enrolled in two international, multicentre, randomized controlled trials of epratuzumab (ALLEVIATE-1 and -2) and a long-term extension study (SL0006). Methods. Ninety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strand, Vibeke, Petri, Michelle, Kalunian, Kenneth, Gordon, Caroline, Wallace, Daniel J., Hobbs, Kathryn, Kelley, Lexy, Kilgallen, Brian, Wegener, William A., Goldenberg, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930886/ https://www.ncbi.nlm.nih.gov/pubmed/24273022 http://dx.doi.org/10.1093/rheumatology/ket378

Ejemplares similares

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
por: Wallace, Daniel J, et al.
Publicado: (2014)

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2006)

Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2008)

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study
por: Steinfeld, Serge D, et al.
Publicado: (2006)

Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells
por: Chang, Chien-Hsing, et al.
Publicado: (2014)

Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus
por: Al Rayes, Hanan, et al.
Publicado: (2014)

Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients
por: Fleischer, Vanessa, et al.
Publicado: (2015)

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus
por: Daridon, Capucine, et al.
Publicado: (2010)

Vitamin D Levels Are Associated with Expression of SLE, but Not Flare Frequency
por: Squance, Marline L., et al.
Publicado: (2014)

Course of Neuropsychiatric Symptoms during Flares of Systemic Lupus Erythematosus (SLE)
por: Garrett, Gareth, et al.
Publicado: (2017)

Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials
por: Gottenberg, Jacques‐Eric, et al.
Publicado: (2018)

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
por: Merrill, Joan T, et al.
Publicado: (2018)

Exploring lifetime occupational exposure and SLE flare: a patient-focussed pilot study
por: Squance, Marline L, et al.
Publicado: (2014)

SLE-DAS in the First Trimester of Gestation Predicts Maternal Lupus Flares Later in Pregnancy
por: Larosa, Maddalena, et al.
Publicado: (2021)

Effect of Graphene Addition on the Thermal and Persistent Luminescence Properties of Gd(2.994)Ce(0.006)Ga(3)Al(2)O(12) and Gd(2.964)Ce(0.006)Dy(0.03)Ga(3)Al(2)O(12) Ceramics
por: Kujawa, Daniela, et al.
Publicado: (2022)

Insecticidal characteristics and structural identification of the potential active compounds from Streptomyces sp. KR0006: Strain improvement through mutagenesis
por: Kim, Young Sook, et al.
Publicado: (2022)

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
por: Isenberg, David, et al.
Publicado: (2015)

Cutaneous vasculitis in SLE
por: Kallas, Romy, et al.
Publicado: (2020)

SLE clinical trials: impact of missing data on estimating treatment effects
por: Kim, Mimi, et al.
Publicado: (2019)

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
por: Clowse, Megan E. B., et al.
Publicado: (2017)

Anti-dsDNA B-Cell ELISpot as a Monitoring and Flare Prediction Tool in SLE Patients
por: Pérez-Isidro, Albert, et al.
Publicado: (2023)

Prophylactic corticosteroid to prevent pain flare in bone metastases treated by radiotherapy
por: Viani, Gustavo Arruda, et al.
Publicado: (2021)

LCRF‐0006, a small molecule mimetic of the N‐cadherin antagonist peptide ADH‐1, synergistically increases multiple myeloma response to bortezomib
por: Mrozik, Krzysztof M., et al.
Publicado: (2020)

Improving resource utilisation in SLE drug development through innovative trial design
por: Garces, Sandra, et al.
Publicado: (2023)

Varicella zoster virus infections increase the risk of disease flares in patients with SLE: a matched cohort study
por: Sun, Fangfang, et al.
Publicado: (2019)

Associates and predictors of pleurisy or pericarditis in SLE
por: Ryu, Seungwon, et al.
Publicado: (2017)

Good efficacy achieved by telitacicept, corticosteroids and immunosuppressants in the treatment of SLE combined with MOG-AD
por: Tian, Mengxue, et al.
Publicado: (2023)

Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE
por: Gilbert, Mileka, et al.
Publicado: (2021)

Predictors of incident proteinuria among patients with SLE
por: Duarte-García, Alí, et al.
Publicado: (2017)

A99 EFFICACY OF THE IN-HOSPITAL OBSERVATORY PERIOD FOR IBD PATIENTS WITH FLARE TREATED WITH ORAL CORTICOSTEROIDS
por: Buttar, J, et al.
Publicado: (2023)

Cell-bound complement activation products associate with lupus severity in SLE
por: Arriens, Cristina, et al.
Publicado: (2020)

Clinical impact of biologic therapy in the treatment of SLE
por: Wallace, Daniel J
Publicado: (2013)

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

Loss of antiphospholipid antibody positivity post-thrombosis in SLE
por: Khawaja, Muznay, et al.
Publicado: (2020)

Genome-wide DNA methylation analysis of Haloferax volcanii H26 and identification of DNA methyltransferase related PD-(D/E)XK nuclease family protein HVO_A0006
por: Ouellette, Matthew, et al.
Publicado: (2015)

Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)
por: Williams-Hall, Rebecca, et al.
Publicado: (2022)

Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2022)

Effect of pregnancy on serum cytokines in SLE patients
por: Doria, Andrea, et al.
Publicado: (2012)

Pauci-immune Glomerulonephritis in Systemic Lupus Erythematosus (SLE)
por: Liebowitz, Jason, et al.
Publicado: (2018)

Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can This Be Optimized?
por: Pike, Marilyn C., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9aldastfodq1jmsl4rlknklsbc